ANIP
$74.67-0.15 (-0.20%)
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
Recent News
ANI Pharmaceuticals Expands Ophthalmology Reach As Valuation Signals Upside Potential
ANI Pharmaceuticals agreed to acquire Alimera Sciences, adding eye disease treatments Iluvien and Yutiq to its rare disease portfolio. The deal expands ANI Pharmaceuticals' presence in diabetic macular edema and non infectious uveitis, two niche ophthalmic indications. For investors watching NasdaqGM:ANIP, the Alimera acquisition comes with the stock at $74.67 and a 1 year return of 16.2%. Over 3 years, the share price return is 98.5%, and over 5 years it is 128.5%, which indicates that the...
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset
NVS bets $2B upfront on SNV4818 to expand precision oncology in breast cancer, targeting a large mutation-driven market and boosting long-term pipeline growth.
2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Question
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Encompass Health Expands in Delaware With New 40-Bed Unit Plans
EHC unveils a 40-bed inpatient rehabilitation hospital in Bear, DE, adding advanced therapy services and expanding its in-state footprint.
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
XENE shares gain 20% in 3 months as positive phase III data for epilepsy drug azetukalner and pipeline progress boost outlook and investor confidence.